Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma

被引：0
|
作者：
T. Y. S. Le Large
M. F. Bijlsma
B. El Hassouni
G. Mantini
T. Lagerweij
A. A. Henneman
N. Funel
B. Kok
T. V. Pham
R. de Haas
L. Morelli
J. C. Knol
S. R. Piersma
G. Kazemier
H. W. M. van Laarhoven
E. Giovannetti
C. R. Jimenez
机构：
[1] VU University Amsterdam,Department of Surgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[2] VU University,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers
[3] University of Amsterdam,Laboratory for Experimental Oncology and Radiobiology, Cancer Center Amsterdam, Amsterdam University Medical Center
[4] VU University,OncoProteomics Laboratory, Department of Medical Oncology, Cancer, Cancer Center Amsterdam, Amsterdam University Medical Centers
[5] Oncode Institute,Cancer Pharmacology Lab, AIRC
[6] Fondazione Pisana per la Scienza,Start
[7] VU University Amsterdam,Up
[8] Azienda Ospedaliero-Universitaria Pisana,Department of Neurosurgery, Cancer Center Amsterdam, Amsterdam University Medical Centers
[9] University of Amsterdam,Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center
来源：
Journal of Experimental & Clinical Cancer Research | / 40卷
关键词：
Pancreatic cancer; Therapy; FAK; EPHA2; MET; Phosphoproteomics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [22] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [23] Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
    Tong, Yi Tat
    Lai, Zongshan
    Katz, Matthew H. G.
    Prakash, Laura R.
    Wang, Hua
    Chatterjee, Deyali
    Kim, Michael
    Tzeng, Ching-Wei D.
    Lee, Jeffrey E. E.
    Ikoma, Naruhiko
    Rashid, Asif
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    CANCERS, 2023, 15 (09)
  • [24] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy
    Tong, Yi Tat
    Lai, Zongshan
    Katz, Matthew
    Prakash, Laura
    Wang, Hua
    Chatterjee, Deyali
    Kim, Michael
    Tzeng, Ching-Wei
    Lee, Jeffrey
    Ikoma, Naruhiko
    Rashid, Asif
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene
    Maitra, Anirban
    Wang, Huamin
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1236 - 1236
  • [25] The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
    Palacio, Sofia
    Hosein, Peter J.
    Reis, Isildinha
    Akunyili, Ikechukwu I.
    Ernani, Vinicius
    Pollack, Terri
    Macintyre, Jessica
    Restrepo, Maria H.
    Merchan, Jaime R.
    Lima, Caio M. Rocha
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (01) : 135 - 139
  • [26] The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
    Peron, Julien
    Giai, Joris
    Maucort-Boulch, Delphine
    Buyse, Marc
    PANCREAS, 2019, 48 (02) : 275 - 280
  • [27] Pathologic Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy
    Tong, Yi Tat
    Lai, Zongshan
    Katz, Matthew
    Prakash, Laura
    Wang, Hua
    Chatterjee, Deyali
    Kim, Michael
    Tzeng, Ching-Wei
    Lee, Jeffrey
    Ikoma, Naruhiko
    Rashid, Asif
    Wolff, Robert A.
    Zhao, Dan
    Koay, Eugene
    Maitra, Anirban
    Wang, Huamin
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1236 - 1236
  • [28] Cost-effectiveness of NALIRIFOX versus Nab-paclitaxel and gemcitabine in previously untreated metastatic pancreatic ductal adenocarcinoma
    Wenjie Liu
    Yuting Fang
    Chao Zhang
    Midan Xiang
    Lijuan Qi
    Aijiang Su
    Yongkun Sun
    BMC Gastroenterology, 25 (1)
  • [29] Nab-paclitaxel and gemcitabine for the treatment of pancreatic adenocarcinoma at an academic center.
    Gahvari, Zhubin
    LoConte, Noelle K.
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Cho, Clifford Suhyun
    Winslow, Emily
    Weber, Sharon M.
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] nab-Paclitaxel for the treatment of pancreatic cancer
    Kim, George
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 85 - 96
12345